Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 69 of 69 matching drugs for TYK2 — including drugs targeting any of its 30 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
ioa-244, avelumab injection, pemetrexed, cisplatin, ruxolitinib TYK2 Direct 2
lmb-100, tofacitinib, mesothelin expression TYK2 Direct 1
ruxolitinib TYK2 Direct 1
ruxolitinib, erlotinib TYK2 Direct 1
ruxolitinib, radiation, temozolomide TYK2 Direct 1
trametinib, ruxolitinib TYK2 Direct 1
trametinib, ruxolitinib, retifanlimab TYK2 Direct 1
tofacitinib TYK2 Direct yes 0
tofacitinib citrate TYK2 Direct yes 0
upadacitinib TYK2 Direct yes 0
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib ERBB4 SSL via ERBB4 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib LCK SSL via LCK 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib SRC SSL via SRC 3
afatinib ERBB4 SSL via ERBB4 yes 3
mrtx849, pembrolizumab, cetuximab, afatinib ERBB4 SSL via ERBB4 3
tucatinib ERBB3 SSL via ERBB3 3
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel ERBB4 SSL via ERBB4 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment LCK SSL via LCK 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment SRC SSL via SRC 2
nintedanib LCK SSL via LCK 2
nintedanib SRC SSL via SRC 2
nintedanib, pembrolizumab LCK SSL via LCK 2
nintedanib, pembrolizumab SRC SSL via SRC 2
afatinib, biopsy, biospecimen collection, computed tomography, echocardiography, magnetic resonance imaging, radionuclide imaging ERBB4 SSL via ERBB4 1
afatinib, dasatinib, palbociclib, everolimus, olaparib ERBB4 SSL via ERBB4 1
afatinib, dasatinib, palbociclib, everolimus, olaparib LCK SSL via LCK 1
afatinib, dasatinib, palbociclib, everolimus, olaparib SRC SSL via SRC 1
afatinib, docetaxel, radiation therapy ERBB4 SSL via ERBB4 1
afatinib, gefitinib ERBB4 SSL via ERBB4 1
afatinib, irinotecan ERBB4 SSL via ERBB4 1
bevacizumab, dasatinib, placebo LCK SSL via LCK 1
bevacizumab, dasatinib, placebo SRC SSL via SRC 1
bosutinib CAMK2G SSL via CAMK2G 1
bosutinib SRC SSL via SRC yes 1
byl719, poziotinib, nintedanib, abemaciclib, durvalumab,tremelimumab LCK SSL via LCK 1
byl719, poziotinib, nintedanib, abemaciclib, durvalumab,tremelimumab SRC SSL via SRC 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride LCK SSL via LCK 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride SRC SSL via SRC 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method LCK SSL via LCK 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method SRC SSL via SRC 1
dasatinib, laboratory biomarker analysis, physiologic testing LCK SSL via LCK 1
dasatinib, laboratory biomarker analysis, physiologic testing SRC SSL via SRC 1
dasatinib, mfolfox6 LCK SSL via LCK 1
dasatinib, mfolfox6 SRC SSL via SRC 1
dasatinib, pharmacological study LCK SSL via LCK 1
dasatinib, pharmacological study SRC SSL via SRC 1
dasatinib, temozolomide, placebo, radiation therapy LCK SSL via LCK 1
dasatinib, temozolomide, placebo, radiation therapy SRC SSL via SRC 1
disitamab vedotin, tucatinib ERBB3 SSL via ERBB3 1
disulfiram, copper, alkylating agents GPI SSL via GPI 1
inotuzumab ozogamicin, flag (fludarabine, cytarabine and g-csf), hidac (high dose cytarabine), cytarabine and mitoxantrone CD22 SSL via CD22 1
palbociclib, afatinib ERBB4 SSL via ERBB4 1
ponatinib LCK SSL via LCK 1
ponatinib SRC SSL via SRC 1
tucatinib, trastuzumab, oxaliplatin, leucovorin, fluorouracil, capecitabine, pembrolizumab ERBB3 SSL via ERBB3 1
tucatinib, trastuzumab, ramucirumab, paclitaxel, tucatinib placebo, trastuzumab placebo ERBB3 SSL via ERBB3 1
afatinib dimaleate ERBB4 SSL via ERBB4 yes 0
dacomitinib ERBB4 SSL via ERBB4 yes 0
dasatinib LCK SSL via LCK yes 0
dasatinib SRC SSL via SRC yes 0
neratinib ERBB4 SSL via ERBB4 yes 0
neratinib maleate ERBB4 SSL via ERBB4 yes 0
pazopanib LCK SSL via LCK yes 0
pazopanib hydrochloride LCK SSL via LCK yes 0
tirbanibulin SRC SSL via SRC yes 0
vandetanib ERBB3 SSL via ERBB3 yes 0
vandetanib ERBB4 SSL via ERBB4 yes 0
vandetanib LCK SSL via LCK yes 0
vandetanib SRC SSL via SRC yes 0
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.